

Glenn Chertow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6031900/publications.pdf>

Version: 2024-02-01

583
papers

67,201
citations

1233

110
h-index

832

245
g-index

594
all docs

594
docs citations

594
times ranked

42243
citing authors

#	ARTICLE	IF	CITATIONS
1	Removing Race from eGFR calculations: Implications for Urologic Care. <i>Urology</i> , 2022, 162, 42-48.	0.5	8
2	The CALCIPHYX study: a randomized, double-blind, placebo-controlled, Phase 3 clinical trial of SNF472 for the treatment of calciphylaxis. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 136-144.	1.4	13
3	Consensus-Based Recommendations for the Management of Hyperkalemia in the Hemodialysis Setting. , 2022, 32, e1-e14.		9
4	A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. <i>Kidney International</i> , 2022, 101, 174-184.	2.6	53
5	Clinical laboratory tests associated with survival in patients with metastatic renal cell carcinoma: A Laboratory Wide Association Study (LWAS). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 12.e23-12.e30.	0.8	3
6	Twenty-four-hour Urine Testing and Urinary Stone Disease Recurrence in Veterans. <i>Urology</i> , 2022, 159, 33-40.	0.5	4
7	COVID-19 Vaccine Type and Humoral Immune Response in Patients Receiving Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 33-37.	3.0	46
8	SARS-CoV-2 Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Kidney Transplant Recipients. <i>Kidney360</i> , 2022, 3, 10.34067/KID.0005732021.	0.9	9
9	Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1647-1656.	0.4	48
10	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. <i>Lancet Diabetes and Endocrinology</i> , the, 2022, 10, 24-34.	5.5	40
11	Dysgeusia and Dysosmia in Chronic Kidney Disease: NHANES 2011-2014. , 2022, 32, 537-541.		2
12	Quã©telet (body mass) index and effects of dapagliflozin in chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 827-837.	2.2	8
13	Renal Morbidity Following Radical Cystectomy in Patients with Bladder Cancer. <i>European Urology Open Science</i> , 2022, 35, 29-36.	0.2	2
14	Cardiovascular outcomes associated with prescription of sodiumâ€¦glucose coâ€¦transporterâ€¦2 inhibitors versus dipeptidyl peptidaseâ€¦4 inhibitors in patients with diabetes and chronic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 928-937.	2.2	2
15	Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions. <i>Kidney International Reports</i> , 2022, 7, 699-707.	0.4	6
16	Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease. <i>Journal of General Internal Medicine</i> , 2022, 37, 3380-3387.	1.3	15
17	Emerging Role of Clinical Genetics in CKD. <i>Kidney Medicine</i> , 2022, 4, 100435.	1.0	12
18	SARS-CoV-2 Vaccine Antibody Response and Breakthrough Infection in Patients Receiving Dialysis. <i>Annals of Internal Medicine</i> , 2022, 175, 371-378.	2.0	55

#	ARTICLE	IF	CITATIONS
19	Breaking the Barriers to Innovation in Kidney Care. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 591-593.	2.2	3
20	The Kidney Protective Effects of the Sodium-Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists. <i>Kidney International Reports</i> , 2022, 7, 436-443.	0.4	36
21	Changing the Trajectory of Heart Failure and Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, , CJN.00470122.	2.2	2
22	Trends in Cost Attributable to Kidney Transplantation Evaluation and Waiting List Management in the United States, 2012-2017. <i>JAMA Network Open</i> , 2022, 5, e221847.	2.8	11
23	Dialysis Initiation in Patients With Chronic Coronary Disease and Advanced Chronic Kidney Disease in ISCHEMIA-CKD. <i>Journal of the American Heart Association</i> , 2022, 11, e022003.	1.6	6
24	SARS-CoV-2 Booster Vaccine Response among Patients Receiving Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 1036-1038.	2.2	16
25	Long-Term Clinical Impact of Contrast-Associated Acute Kidney Injury Following PCI. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 753-766.	1.1	31
26	Trends in Coronary Artery Disease Screening before Kidney Transplantation. <i>Kidney360</i> , 2022, 3, 516-523.	0.9	1
27	Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. <i>Diabetologia</i> , 2022, 65, 1085-1097.	2.9	28
28	FC082: Effects of Dapagliflozin in Patients with Chronic Kidney Disease According to Background Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Dose. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
29	MO536: Cardiovascular Events in Patients With Anemia Associated With Non-Dialysis-Dependent Chronic Kidney Disease: Regional Analysis of Patients not Previously Treated With Erythropoiesis-Stimulating Agents in The PRO2TECT Trial. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
30	MO532: Cardiovascular Events in Patients With Non-Dialysis-Dependent Chronic Kidney Disease and Anemia: Regional Analysis of Patients Previously Treated With Erythropoiesis-Stimulating Agents in the PRO2TECT Trial. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
31	Reply. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 1093-1094.	1.1	0
32	Clinical and Quality-of-Life Outcomes Following Invasive vs Conservative Treatment of Patients With Chronic Coronary Disease Across the Spectrum of Kidney Function. <i>JAMA Cardiology</i> , 2022, 7, 825.	3.0	2
33	Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2039-2048.	0.4	20
34	Innovation in hemodialysis: Using the Biodesign process to identify unmet needs. <i>Journal of Vascular Access</i> , 2021, 22, 509-514.	0.5	5
35	Fibroblast growth factor 23 as a risk factor for cardiovascular events and mortality in patients in the EVOLVE trial. <i>Hemodialysis International</i> , 2021, 25, 78-85.	0.4	3
36	Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. <i>Circulation</i> , 2021, 143, 438-448.	1.6	85

#	ARTICLE	IF	CITATIONS
37	Toward telemedicine-compatible physical functioning assessments in kidney transplant candidates. <i>Clinical Transplantation</i> , 2021, 35, e14173.	0.8	9
38	Laboratory-wide association study of survival with prostate cancer. <i>Cancer</i> , 2021, 127, 1102-1113.	2.0	6
39	Urate Lowering With Combination Therapy in CKD: Reason for Optimism or Einstein's Definition of Insanity?. <i>American Journal of Kidney Diseases</i> , 2021, 77, 478-480.	2.1	3
40	Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 22-31.	5.5	287
41	Race and Place in ESKD. <i>Kidney International Reports</i> , 2021, 6, 252-253.	0.4	0
42	Combination treatment with tenapanor and sevelamer synergistically reduces urinary phosphorus excretion in rats. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, F133-F144.	1.3	7
43	Prolonged Hospitalization Following Acute Respiratory Failure. <i>Chest</i> , 2021, 159, 1867-1874.	0.4	5
44	Self-care training using the Tablo hemodialysis system. <i>Hemodialysis International</i> , 2021, 25, 12-19.	0.4	0
45	Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics. <i>American Heart Journal</i> , 2021, 235, 1-11.	1.2	9
46	Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD. <i>Clinical and Translational Science</i> , 2021, 14, 299-309.	1.5	18
47	Trial design and baseline characteristics of CaLIPSO: a randomized, double-blind placebo-controlled trial of SNF472 in patients receiving haemodialysis with cardiovascular calcification. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 366-374.	1.4	8
48	The Contribution of Known Familial Cardiovascular Disease Genes to Sudden Cardiac Death in Patients Undergoing Hemodialysis. <i>CardioRenal Medicine</i> , 2021, 11, 174-183.	0.7	0
49	Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome. <i>American Journal of Nephrology</i> , 2021, 52, 180-189.	1.4	31
50	Performance versus Risk Factor-Based Approaches to Coronary Artery Disease Screening in Waitlisted Kidney Transplant Candidates. <i>CardioRenal Medicine</i> , 2021, 11, 140-150.	0.7	1
51	And Then There Were Three: Effects of Pretransplant Dialysis on Multiorgan Transplantation. <i>Transplantation Direct</i> , 2021, 7, e657.	0.8	3
52	Cost Structures of US Organ Procurement Organizations. <i>Transplantation</i> , 2021, 105, 2612-2619.	0.5	3
53	Chronic kidney disease, atherosclerotic plaque characteristics on carotid magnetic resonance imaging, and cardiovascular outcomes. <i>BMC Nephrology</i> , 2021, 22, 69.	0.8	6
54	A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY). <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1465-1473.	3.0	45

#	ARTICLE	IF	CITATIONS
55	Aldosterone sensitivity: an opportunity to explore the pathogenesis of hypertension. American Journal of Physiology - Renal Physiology, 2021, 320, F325-F335.	1.3	7
56	Invasive Management of Coronary Artery Disease in Advanced Renal Disease. Kidney International Reports, 2021, 6, 1513-1524.	0.4	5
57	Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. European Heart Journal, 2021, 42, 1216-1227.	1.0	75
58	Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. New England Journal of Medicine, 2021, 384, 1601-1612.	13.9	106
59	Targeting Sedentary Behavior in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 717-726.	2.2	12
60	Vadadustat in Patients with Anemia and Non-dialysis-Dependent CKD. New England Journal of Medicine, 2021, 384, 1589-1600.	13.9	137
61	SARS-CoV-2 Vaccine Acceptability in Patients on Hemodialysis: A Nationwide Survey. Journal of the American Society of Nephrology: JASN, 2021, 32, 1575-1581.	3.0	46
62	Effects of Myo-inositol Hexaphosphate (SNF472) on Bone Mineral Density in Patients Receiving Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 736-745.	2.2	11
63	Laboratory correlates of SARS-CoV-2 seropositivity in a nationwide sample of patients on dialysis in the U.S.. PLoS ONE, 2021, 16, e0249466.	1.1	1
64	SNF472: mechanism of action and results from clinical trials. Current Opinion in Nephrology and Hypertension, 2021, 30, 424-429.	1.0	7
65	Estimated impact of novel coronavirus-19 and transplant center inactivity on end-stage renal disease-related patient mortality in the United States. Clinical Transplantation, 2021, 35, e14292.	0.8	3
66	The organ procurement costs of expanding deceased donor organ acceptance criteria: Evidence from a cost function model. American Journal of Transplantation, 2021, 21, 3694-3703.	2.6	4
67	Body Composition Changes Following Dialysis Initiation and Cardiovascular and Mortality Outcomes in CRIC (Chronic Renal Insufficiency Cohort): A Bioimpedance Analysis Substudy. Kidney Medicine, 2021, 3, 327-334.e1.	1.0	6
68	National Estimates of CKD Prevalence and Potential Impact of Estimating Glomerular Filtration Rate Without Race. Journal of the American Society of Nephrology: JASN, 2021, 32, 1454-1463.	3.0	28
69	MO518INSIDE CKD: MODELLING THE ECONOMIC BURDEN OF CHRONIC KIDNEY DISEASE IN THE AMERICAS AND THE ASIA-PACIFIC REGION USING PATIENT-LEVEL MICROSIMULATION. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
70	Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. Diabetes Care, 2021, 44, 1894-1897.	4.3	47
71	Antibody Response to COVID-19 Vaccination in Patients Receiving Dialysis. Journal of the American Society of Nephrology: JASN, 2021, 32, 2435-2438.	3.0	91
72	Reducing the Shortage of Transplant Kidneys: A Lost Opportunity for the US Health Resources and Services Administration (HRSA). American Journal of Kidney Diseases, 2021, 77, 963-966.	2.1	2

#	ARTICLE	IF	CITATIONS
73	Karnofsky Performance Score“Failure to Thrive as a Frailty Proxy?. Transplantation Direct, 2021, 7, e708.	0.8	6
74	Primary Nephrotic Syndrome and Risks of ESKD, Cardiovascular Events, and Death: The Kaiser Permanente Nephrotic Syndrome Study. Journal of the American Society of Nephrology: JASN, 2021, 32, 2303-2314.	3.0	27
75	The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure. Journal of Cardiac Failure, 2021, 27, 1447-1455.	0.7	14
76	Challenging Assumptions of Outcomes and Costs Comparing Peritoneal and Hemodialysis. Value in Health, 2021, 24, 1592-1602.	0.1	8
77	Chronic Inflammation in Chronic Kidney Disease Progression: Role of Nrf2. Kidney International Reports, 2021, 6, 1775-1787.	0.4	100
78	Patient-Reported Experiences with Dialysis Care and Provider Visit Frequency. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1052-1060.	2.2	0
79	Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic. JAMA Network Open, 2021, 4, e2116572.	2.8	12
80	A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney International, 2021, 100, 215-224.	2.6	182
81	Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2021, 32, 2352-2361.	3.0	88
82	Serial SARS-CoV-2 Receptor-Binding Domain Antibody Responses in Patients Receiving Dialysis. Annals of Internal Medicine, 2021, 174, 1073-1080.	2.0	21
83	Barriers to ACEI/ARB Use in Proteinuric Chronic Kidney Disease: An Observational Study. Mayo Clinic Proceedings, 2021, 96, 2114-2122.	1.4	15
84	Safety and Efficacy of Tenapanor for Long-term Serum Phosphate Control in Maintenance Dialysis: A 52-Week Randomized Phase 3 Trial (PHREEDOM). Kidney360, 2021, 2, 1600-1610.	0.9	12
85	Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure. JACC: Heart Failure, 2021, 9, 807-820.	1.9	49
86	Using an Automated Electronic Health Record Score To Estimate Life Expectancy In Men Diagnosed With Prostate Cancer In The Veterans Health Administration. Urology, 2021, 155, 70-76.	0.5	6
87	Timing of Antihypertensive Medications on Key Outcomes in Hemodialysis: A Cluster Randomized Trial. Kidney360, 2021, 2, 1752-1760.	0.9	4
88	AUTHOR REPLY. Urology, 2021, 155, 76.	0.5	0
89	Effect of a Home-Based Exercise Program on Indices of Physical Function and Quality of Life in Elderly Maintenance Hemodialysis Patients. Kidney and Blood Pressure Research, 2021, 46, 196-206.	0.9	13
90	Association of 152 Biomarker Reference Intervals with All-Cause Mortality in Participants of a General United States Survey from 1999 to 2010. Clinical Chemistry, 2021, 67, 500-507.	1.5	3

#	ARTICLE	IF	CITATIONS
91	The effects of dapagliflozin on kidney and cardiovascular outcomes in patients with chronic kidney disease with and without heart failure. <i>European Heart Journal</i> , 2021, 42, .	1.0	0
92	The Predialysis Serum Sodium Level Modifies the Effect of Hemodialysis Frequency on Left-Ventricular Mass: The Frequent Hemodialysis Network Trials. <i>Kidney and Blood Pressure Research</i> , 2021, 46, 768-776.	0.9	2
93	Population-based identification and temporal trend of children with primary nephrotic syndrome: The Kaiser Permanente nephrotic syndrome study. <i>PLoS ONE</i> , 2021, 16, e0257674.	1.1	3
94	Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 743-754.	5.5	87
95	Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 755-766.	5.5	86
96	Obesity and Incident Kidney Disease: Busting the Myth of Metabolically Healthy Obesity. <i>American Journal of Kidney Diseases</i> , 2021, , .	2.1	0
97	Outcomes after left ventricular assist device implantation in patients with acute kidney injury. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 477-486.e3.	0.4	11
98	One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1769-1778.	0.4	25
99	Understanding the role of the cytoprotective transcription factor nuclear factor erythroid 2-related factor 2—lessons from evolution, the animal kingdom and rare progeroid syndromes. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 2036-2045.	0.4	48
100	Toward Greater Scrutiny of Dialysate Flow: Reply to the Letter to the Editor of Dr. Molano-Triviño and Colleagues. <i>Blood Purification</i> , 2020, 49, 123-124.	0.9	0
101	Safety and efficacy of the Tablo hemodialysis system for in-center and home hemodialysis. <i>Hemodialysis International</i> , 2020, 24, 22-28.	0.4	10
102	Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 75-84.	1.4	20
103	Preparing for Hemodialysis. , 2020, , 1157-1173.		1
104	Slowing Progression of Cardiovascular Calcification With SNF472 in Patients on Hemodialysis. <i>Circulation</i> , 2020, 141, 728-739.	1.6	104
105	Intradialytic Symptoms and Recovery Time in Patients on Thrice-Weekly In-Center Hemodialysis: A Cross-sectional Online Survey. <i>Kidney Medicine</i> , 2020, 2, 125-130.	1.0	13
106	Central venous pressure and the risk of diuretic-associated acute kidney injury in patients after cardiac surgery. <i>American Heart Journal</i> , 2020, 221, 67-73.	1.2	15
107	Effect of Intensive vs Standard Blood Pressure Treatment Upon Erectile Function in Hypertensive Men: Findings From the Systolic Blood Pressure Intervention Trial. <i>Journal of Sexual Medicine</i> , 2020, 17, 238-248.	0.3	7
108	A double-blind, randomized, placebo-controlled pilot trial to evaluate safety and efficacy of vorapaxar on arteriovenous fistula maturation. <i>Journal of Vascular Access</i> , 2020, 21, 467-474.	0.5	1

#	ARTICLE	IF	CITATIONS
109	Defining a Willingness-to-transplant Threshold in an Era of Organ Scarcity: Simultaneous Liver& kidney Transplant as a Case Example. <i>Transplantation</i> , 2020, 104, 387-394.	0.5	13
110	Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study. <i>Lancet, The</i> , 2020, 396, 1335-1344.	6.3	257
111	Dapagliflozin in Patients with Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 383, 1436-1446.	13.9	2,523
112	Correlates and Consequences of High Serum Irisin Concentration in Patients on Hemodialysis: A Longitudinal Analysis. , 2020, 31, 389-396.		2
113	Does really central venous pressure affect the risk of diuretic-associated acute kidney injury after cardiac surgery?. <i>American Heart Journal</i> , 2020, 226, 252.	1.2	0
114	Alport Syndrome Classification and Management. <i>Kidney Medicine</i> , 2020, 2, 639-649.	1.0	45
115	Analysis of Primary Hyperparathyroidism Screening Among US Veterans With Kidney Stones. <i>JAMA Surgery</i> , 2020, 155, 861.	2.2	26
116	The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1700-1711.	0.4	107
117	Patient&reported outcomes from the investigational device exemption study of the Tablo hemodialysis system. <i>Hemodialysis International</i> , 2020, 24, 480-486.	0.4	2
118	Effects of SNF472, a Novel Inhibitor of Hydroxyapatite Crystallization in Patients Receiving Hemodialysis &” Subgroup Analyses of the CALIPSO Trial. <i>Kidney International Reports</i> , 2020, 5, 2178-2182.	0.4	11
119	Factors Associated With Failure to Achieve the Intensive Blood Pressure Target in the Systolic Blood Pressure Intervention Trial (SPRINT). <i>Hypertension</i> , 2020, 76, 1725-1733.	1.3	4
120	The Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Blood Pressure Lowering on Cardiovascular Outcomes and All-Cause Mortality in Type 2 Diabetes. <i>Diabetes Care</i> , 2020, 43, 1878-1884.	4.3	31
121	Safety-Net Care for Maintenance Dialysis in the United States. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 424-433.	3.0	5
122	Differential effects of phosphate binders on vitamin D metabolism in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 616-623.	0.4	5
123	Management of Coronary Disease in Patients with Advanced Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1608-1618.	13.9	310
124	Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1619-1628.	13.9	56
125	Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. <i>Circulation</i> , 2020, 141, 1384-1392.	1.6	87
126	Early Delays in Insurance Coverage and Long-term Use of Home-based Peritoneal Dialysis. <i>Medical Care</i> , 2020, 58, 632-642.	1.1	9

#	ARTICLE	IF	CITATIONS
127	Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 274-282.	0.4	168
128	Screening Rates for Primary Aldosteronism in Resistant Hypertension. <i>Hypertension</i> , 2020, 75, 650-659.	1.3	92
129	AKI—A Relevant Safety End Point?. <i>American Journal of Kidney Diseases</i> , 2020, 75, 508-512.	2.1	13
130	Targeting Vascular Calcification in Chronic Kidney Disease. <i>JACC Basic To Translational Science</i> , 2020, 5, 398-412.	1.9	95
131	Dedicated kidney disease—focused outcome trials with sodium—glucose cotransporter—2 inhibitors: Lessons from CRENDENCE and expectations from DAPA—HF, DAPA—CKD, and EMPA—KIDNEY. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 46-54.	2.2	36
132	Osteoporosis, Fractures, and Bone Mineral Density Screening in Veterans With Kidney Stone Disease. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 872-878.	3.1	11
133	Physical Performance Testing in Kidney Transplant Candidates at the Top of the Waitlist. <i>American Journal of Kidney Diseases</i> , 2020, 76, 815-825.	2.1	17
134	Drug Development in Kidney Disease: Proceedings From a Multistakeholder Conference. <i>American Journal of Kidney Diseases</i> , 2020, 76, 842-850.	2.1	4
135	The —Advancing American Kidney Health—Executive Order: Challenges and Opportunities for the Large Dialysis Organizations. <i>American Journal of Kidney Diseases</i> , 2020, 76, 731-734.	2.1	13
136	Urinary Stone Disease in Pregnancy: A Claims Based Analysis of 1.4 Million Patients. <i>Journal of Urology</i> , 2020, 203, 957-961.	0.2	12
137	Baseline Diastolic Blood Pressure and Cardiovascular Outcomes in SPRINT Participants with Chronic Kidney Disease. <i>Kidney360</i> , 2020, 1, 368-375.	0.9	7
138	Patient and Provider Characteristics Associated With Sodium—Glucose Cotransporter 2 Inhibitor Prescription in Patients With Diabetes and Proteinuric Chronic Kidney Disease. <i>Clinical Diabetes</i> , 2020, 38, 240-247.	1.2	9
139	The Urine Albumin-to-Creatinine Ratio and Kidney Function after Nephrectomy. <i>Journal of Urology</i> , 2020, 204, 231-238.	0.2	9
140	The ongoing search for a robust clinical prediction model of ICU AKI. <i>Clinical Nephrology</i> , 2020, 93, 160-162.	0.4	1
141	Market Consolidation and Mortality in Patients Initiating Hemodialysis. <i>Value in Health</i> , 2019, 22, 69-76.	0.1	7
142	Low testosterone is associated with frailty, muscle wasting and physical dysfunction among men receiving hemodialysis: a longitudinal analysis. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 802-810.	0.4	38
143	Prevalence of twenty-four hour urine testing in Veterans with urinary stone disease. <i>PLoS ONE</i> , 2019, 14, e0220768.	1.1	8
144	Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 107402.	1.2	25

#	ARTICLE	IF	CITATIONS
145	Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients. <i>Kidney International Reports</i> , 2019, 4, 987-994.	0.4	12
146	A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1495-1504.	3.0	53
147	Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1523-1533.	3.0	41
148	Influence of Prediabetes on the Effects of Intensive Systolic Blood Pressure Control on Kidney Events. <i>American Journal of Hypertension</i> , 2019, 32, 1170-1177.	1.0	2
149	Association of Hospitalization and Mortality Among Patients Initiating Dialysis With Hemodialysis Facility Ownership and Acquisitions. <i>JAMA Network Open</i> , 2019, 2, e193987.	2.8	13
150	Percutaneous Kidney Biopsy and the Utilization of Blood Transfusion and Renal Angiography Among Hospitalized Adults. <i>Kidney International Reports</i> , 2019, 4, 1435-1445.	0.4	10
151	Current Status of Angiotensin Receptor Blocker Recalls. <i>Hypertension</i> , 2019, 74, 1275-1278.	1.3	12
152	Effects of Selonsertib in Patients with Diabetic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1980-1990.	3.0	72
153	Antidiabetic medication use in patients with type 2 diabetes and chronic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 107423.	1.2	2
154	Differential Molecular Modeling Predictions of Mid and Conventional Dialysate Flows. <i>Blood Purification</i> , 2019, 47, 369-376.	0.9	3
155	Fibroblast Growth Factor 23 Genotype and Cardiovascular Disease in Patients Undergoing Hemodialysis. <i>American Journal of Nephrology</i> , 2019, 49, 125-132.	1.4	9
156	Trimethylamine N-Oxide and Cardiovascular Outcomes in Patients with ESKD Receiving Maintenance Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 261-267.	2.2	48
157	Excess Deaths Attributable to Influenza-Like Illness in the ESRD Population. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 346-353.	3.0	29
158	Chronic Kidney Disease and the Adiposity Paradox: Valid or Confounded?. , 2019, 29, 521-528.		12
159	Prospective Biopsy-Based Study of CKD of Unknown Etiology in Sri Lanka. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 224-232.	2.2	27
160	Challenges in Assessing the Burden of Hospitalized Heart Failure in End-Stage Kidney Disease. <i>Journal of Cardiac Failure</i> , 2019, 25, 534-536.	0.7	0
161	Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease. <i>Kidney International</i> , 2019, 96, 1030-1036.	2.6	26
162	Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 641-652.	3.0	83

#	ARTICLE	IF	CITATIONS
163	Hypertension Hot Potato “Anatomy of the Angiotensin-Receptor Blocker Recalls. <i>New England Journal of Medicine</i> , 2019, 380, 1589-1591.	13.9	37
164	Treatment of metabolic acidosis with an intestinal binder. <i>Lancet, The</i> , 2019, 393, 1387-1388.	6.3	2
165	An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism. <i>PLoS ONE</i> , 2019, 14, e0213774.	1.1	12
166	Paying for Hemodialysis in Kerala, India: A Description of Household Financial Hardship in the Context of Medical Subsidy. <i>Kidney International Reports</i> , 2019, 4, 390-398.	0.4	28
167	Relative sarcopenia and mortality and the modifying effects of chronic kidney disease and adiposity. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 338-346.	2.9	28
168	Removing Disincentives to Kidney Donation: A Quantitative Analysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1349-1357.	3.0	21
169	Exploring Care Attributes of Nephrologists Ranking Favorably on Measures of Value. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2464-2472.	3.0	4
170	Twenty-Four Hour Urine Testing and Prescriptions for Urinary Stone Disease—Related Medications in Veterans. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1773-1780.	2.2	12
171	Acute Kidney Injury in Children Hospitalized With Diarrheal Illness in the United States. <i>Hospital Pediatrics</i> , 2019, 9, 933-941.	0.6	6
172	Estimated Effects of Early Diuretic Use in Critical Illness. , 2019, 1, e0021.		4
173	Frailty Among Patients Receiving Hemodialysis: Evolution of Components and Associations With Mortality. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 380-386.	1.7	42
174	Prior Hospitalization Burden and the Relatedness of 30-Day Readmissions in Patients Receiving Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 323-335.	3.0	12
175	Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). <i>American Journal of Kidney Diseases</i> , 2019, 73, 309-315.	2.1	18
176	Payer Type, Race/Ethnicity, and the Timing of Surgical Management of Urinary Stone Disease. <i>Journal of Endourology</i> , 2019, 33, 152-158.	1.1	22
177	Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1115-1124.	0.4	36
178	Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 90-99.	0.4	62
179	The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 339-346.	0.4	28
180	Modification of eGFR-Based CKD Definitions: Perfect, or Enemy of the Good?. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1807-1809.	3.0	8

#	ARTICLE	IF	CITATIONS
181	Asymmetric dimethylarginine, erythropoietin resistance, and anemia in CKD. <i>Annals of Translational Medicine</i> , 2019, 7, S86-S86.	0.7	1
182	Updates in Management and Timing of Dialysis in Acute Kidney Injury. <i>Journal of Hospital Medicine</i> , 2019, 14, 232.	0.7	2
183	Testing two (of several) intravenous iron dosing strategies in hemodialysis. <i>Annals of Translational Medicine</i> , 2019, 7, S129-S129.	0.7	0
184	Updated guidelines for the diagnosis and management of high blood pressure: implications for clinical practice in nephrology. <i>Kidney International</i> , 2018, 93, 768-770.	2.6	3
185	Market Competition and Health Outcomes in Hemodialysis. <i>Health Services Research</i> , 2018, 53, 3680-3703.	1.0	16
186	Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 2018, 71, 851-865.	2.1	362
187	Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 555-563.	5.5	81
188	Hemoglobin response to ferric citrate in patients with nondialysis-dependent chronic kidney disease and iron deficiency anemia. <i>American Journal of Hematology</i> , 2018, 93, E154-E156.	2.0	6
189	Benefits and risks of intensive blood pressure lowering in advanced chronic kidney disease. <i>Journal of Internal Medicine</i> , 2018, 284, 106-107.	2.7	5
190	Antihypertensive medication withholding practices in hemodialysis: A survey study of patients and providers. <i>Hemodialysis International</i> , 2018, 22, 415-418.	0.4	3
191	Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study. <i>American Journal of Nephrology</i> , 2018, 47, 40-47.	1.4	123
192	Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial. <i>American Journal of Hematology</i> , 2018, 93, 683-690.	2.0	100
193	Associations of lipoproteins with cardiovascular and infection-related outcomes in patients receiving hemodialysis. <i>Journal of Clinical Lipidology</i> , 2018, 12, 481-487.e14.	0.6	8
194	Perioperative THR-184 and AKI after Cardiac Surgery. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 670-679.	3.0	35
195	Chronic kidney disease care models in low- and middle-income countries: a systematic review. <i>BMJ Global Health</i> , 2018, 3, e000728.	2.0	57
196	Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial. <i>Kidney International</i> , 2018, 93, 1475-1482.	2.6	41
197	Unplanned Emergency Department Visits and Hospital Admissions Following Ureteroscopy: Do Ureteral Stents Make a Difference?. <i>Urology</i> , 2018, 117, 44-49.	0.5	23
198	Incident CKD after Radical or Partial Nephrectomy. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 207-216.	3.0	55

#	ARTICLE	IF	CITATIONS
199	Allogeneic Mesenchymal Stem Cells for Treatment of AKI after Cardiac Surgery. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 260-267.	3.0	106
200	Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control. <i>Circulation</i> , 2018, 137, 134-143.	1.6	134
201	Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT). <i>American Journal of Kidney Diseases</i> , 2018, 71, 352-361.	2.1	104
202	Causes of Death after a Hospitalization with AKI. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1001-1010.	3.0	71
203	Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine. <i>New England Journal of Medicine</i> , 2018, 378, 603-614.	13.9	399
204	FP152EFFECT OF BARDOXOLONE METHYL TREATMENT ON URINARY ALBUMIN IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE - POST-HOC ANALYSIS FROM BEAM AND BEACON. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i27-i27.	0.4	2
205	The Terrible Toll of the Kidney Shortage. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2775-2776.	3.0	40
206	PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINT. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1816-1824.	2.2	14
207	Would government compensation of living kidney donors exploit the poor? An empirical analysis. <i>PLoS ONE</i> , 2018, 13, e0205655.	1.1	11
208	Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT. <i>Journal of the American Heart Association</i> , 2018, 7, e009326.	1.6	79
209	Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants. <i>PLoS ONE</i> , 2018, 13, e0203305.	1.1	14
210	Prognostic relevance of visit-to-visit office blood pressure variability in Systolic Blood Pressure Intervention Trial: Same data, different conclusions?. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1644-1645.	1.0	2
211	Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 1113-1117.	1.2	14
212	SP104DECREASES IN WEIGHT WITH BARDOXOLONE METHYL IN OBESE PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 4 AND TYPE 2 DIABETES - POST-HOC ANALYSES FROM BEACON. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i379-i379.	0.4	2
213	Ferumoxylol for the treatment of iron deficiency anemia. <i>Expert Review of Hematology</i> , 2018, 11, 829-834.	1.0	35
214	Patient-Reported Experiences of Dialysis Care Within a National Pay-for-Performance System. <i>JAMA Internal Medicine</i> , 2018, 178, 1358.	2.6	24
215	Use of Estimating Equations for Dosing Antimicrobials in Patients with Acute Kidney Injury Not Receiving Renal Replacement Therapy. <i>Journal of Clinical Medicine</i> , 2018, 7, 211.	1.0	8
216	Effects of calcimimetics on long-term outcomes in dialysis patients: literature review and Bayesian meta-analysis. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 693-707.	0.6	10

#	ARTICLE	IF	CITATIONS
217	Dialysis versus Medical Management at Different Ages and Levels of Kidney Function in Veterans with Advanced CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2169-2177.	3.0	34
218	Angiotensin-related genetic determinants of cardiovascular disease in patients undergoing hemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2018, 34, 1924-1931.	0.4	5
219	Acute Kidney Injury Due to Diarrheal Illness Requiring Hospitalization: Data from the National Inpatient Sample. <i>Journal of General Internal Medicine</i> , 2018, 33, 1520-1527.	1.3	12
220	A response by Strauss et al. to "a comment on the comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia". <i>American Journal of Hematology</i> , 2018, 93, E232-E233.	2.0	0
221	Clinical Outcomes by Race and Ethnicity in the Systolic Blood Pressure Intervention Trial (SPRINT): A Randomized Clinical Trial. <i>American Journal of Hypertension</i> , 2018, 31, 97-107.	1.0	25
222	Comparing Simultaneous Liver-Kidney Transplant Strategies. <i>Transplantation</i> , 2018, 102, e219-e228.	0.5	9
223	International Study of Comparative Health Effectiveness with Medical and Invasive Approaches"Chronic Kidney Disease (ISCHEMIA-CKD): Rationale and design. <i>American Heart Journal</i> , 2018, 205, 42-52.	1.2	44
224	Bioelectrical Impedance Analysis Measures and Clinical Outcomes in CKD. <i>American Journal of Kidney Diseases</i> , 2018, 72, 662-672.	2.1	37
225	Mandating Staffing Ratios in Hemodialysis Facilities. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1110-1112.	2.2	13
226	FO022BARDOXOLONE METHYL PREVENTS EGFR DECLINE IN PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 4 AND TYPE 2 DIABETES - POST-HOC ANALYSES FROM BEACON. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i10-i10.	0.4	2
227	Randomized trial of intravenous iron-induced hypophosphatemia. <i>JCI Insight</i> , 2018, 3, .	2.3	127
228	Cost-effectiveness of multidisciplinary care in mild to moderate chronic kidney disease in the United States: A modeling study. <i>PLoS Medicine</i> , 2018, 15, e1002532.	3.9	44
229	Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 156.	3.8	213
230	Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1933-1942.	3.0	78
231	Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1851-1858.	3.0	92
232	Patients receiving frequent hemodialysis have better health-related quality of life compared to patients receiving conventional hemodialysis. <i>Kidney International</i> , 2017, 91, 746-754.	2.6	78
233	Limited reduction in uremic solute concentrations with increased dialysis frequency and time in the Frequent Hemodialysis Network Daily Trial. <i>Kidney International</i> , 2017, 91, 1186-1192.	2.6	55
234	Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 146.	3.8	122

#	ARTICLE	IF	CITATIONS
235	Warfarin and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation Receiving Dialysis: A Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2017, 33, 737-746.	0.8	58
236	Utility in Treating Kidney Failure in End-Stage Liver Disease With Simultaneous Liver-Kidney Transplantation. <i>Transplantation</i> , 2017, 101, 1111-1119.	0.5	26
237	Home Dialysis in the Prospective Payment System Era. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2993-3004.	3.0	52
238	Dosing of Etelcalcetide vs Cinacalcet for Secondary Hyperparathyroidism—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2132.	3.8	4
239	Calcium-Sensing Receptor Genotype and Response to Cinacalcet in Patients Undergoing Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1128-1138.	2.2	21
240	Effects of Intensive BP Control in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2812-2823.	3.0	364
241	Factors Associated with Frailty and Its Trajectory among Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1100-1108.	2.2	120
242	Prehabilitation for kidney transplant candidates: Is it time?. <i>Clinical Transplantation</i> , 2017, 31, e13020.	0.8	39
243	Thyroid function in end stage renal disease and effects of frequent hemodialysis. <i>Hemodialysis International</i> , 2017, 21, 534-541.	0.4	13
244	Sarcopenia and its individual criteria are associated, in part, with mortality among patients on hemodialysis. <i>Kidney International</i> , 2017, 92, 238-247.	2.6	158
245	HDL Glycoprotein Composition and Site-Specific Glycosylation Differentiates Between Clinical Groups and Affects IL-6 Secretion in Lipopolysaccharide-Stimulated Monocytes. <i>Scientific Reports</i> , 2017, 7, 43728.	1.6	28
246	Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Model. <i>Drugs in R and D</i> , 2017, 17, 159-166.	1.1	3
247	Hemodialysis Hospitalizations and Readmissions: The Effects of Payment Reform. <i>American Journal of Kidney Diseases</i> , 2017, 69, 237-246.	2.1	22
248	Blood Calcification Propensity, Cardiovascular Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 315-322.	2.2	122
249	Can twice weekly hemodialysis expand patient access under resource constraints?. <i>Hemodialysis International</i> , 2017, 21, 445-452.	0.4	27
250	Infrequent Provision of Palliative Care to Patients with Dialysis-Requiring AKI. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1744-1752.	2.2	9
251	Associations of Body Mass Index and Body Fat With Markers of Inflammation and Nutrition Among Patients Receiving Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2017, 70, 817-825.	2.1	40
252	Effectiveness of Quality Improvement Strategies for the Management of CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1601-1614.	2.2	19

#	ARTICLE	IF	CITATIONS
253	Visit-to-Visit Office Blood Pressure Variability and Cardiovascular Outcomes in SPRINT (Systolic Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.3	76
254	Receipt of Nephrology Care and Clinical Outcomes Among Veterans With Advanced CKD. American Journal of Kidney Diseases, 2017, 70, 705-714.	2.1	24
255	Donation, Not Disease! A Multiple-Hit Hypothesis on Development of Post-Donation Kidney Disease. Current Transplantation Reports, 2017, 4, 320-326.	0.9	11
256	Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries. BMJ Global Health, 2017, 2, e000453.	2.0	11
257	Declining Rates of Hip Fracture in End-Stage Renal Disease: Analysis From the 2003â€“2011 Nationwide Inpatient Sample. Journal of Bone and Mineral Research, 2017, 32, 2297-2303.	3.1	14
258	Re-evaluation of re-hospitalization and rehabilitation in renal research. Hemodialysis International, 2017, 21, 422-429.	0.4	5
259	Consolidation in the Dialysis Industry, Patient Choice, and Local Market Competition. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 536-545.	2.2	20
260	30-Day Readmissions After an Acute Kidney Injury Hospitalization. American Journal of Medicine, 2017, 130, 163-172.e4.	0.6	61
261	Hyperprolactinemia in endâ€“stage renal disease and effects of frequent hemodialysis. Hemodialysis International, 2017, 21, 190-196.	0.4	30
262	Sarcopenia among patients receiving hemodialysis: weighing the evidence. Journal of Cachexia, Sarcopenia and Muscle, 2017, 8, 57-68.	2.9	80
263	Contemporary Use of Partial Nephrectomy: Are Older Patients With Impaired Kidney Function Being Left Behind?. Urology, 2017, 100, 65-71.	0.5	25
264	Estimating the Risk of Radiocontrast-Associated Nephropathy. Journal of the American Society of Nephrology: JASN, 2017, 28, 653-659.	3.0	182
265	Predialysis volume overload and patientâ€“reported sleep duration and quality in patients receiving hemodialysis. Hemodialysis International, 2017, 21, 133-141.	0.4	10
266	Prevalence of chronic kidney disease and risk factors for its progression: A cross-sectional comparison of Indians living in Indian versus U.S. cities. PLoS ONE, 2017, 12, e0173554.	1.1	21
267	Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease. PLoS ONE, 2017, 12, e0188712.	1.1	22
268	Cost of Acute Kidney Injury in Hospitalized Patients. Journal of Hospital Medicine, 2017, 12, 70-76.	0.7	162
269	Abstract P145: Screening Rates for the Diagnostic Workup of Resistant Hypertension. Hypertension, 2017, 70, .	1.3	0
270	Declining Rates of Inpatient Parathyroidectomy for Primary Hyperparathyroidism in the US. PLoS ONE, 2016, 11, e0161192.	1.1	22

#	ARTICLE	IF	CITATIONS
271	Hip Fracture in Patients With Non-Dialysis-Requiring Chronic Kidney Disease. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1803-1809.	3.1	123
272	Understanding barriers to home-based and self-care in-center hemodialysis. <i>Hemodialysis International</i> , 2016, 20, 235-241.	0.4	12
273	Results of human factors testing in a novel Hemodialysis system designed for ease of patient use. <i>Hemodialysis International</i> , 2016, 20, 643-649.	0.4	12
274	Antihypertensive medications and sexual function in women. <i>Journal of Hypertension</i> , 2016, 34, 1224-1231.	0.3	31
275	How to Diagnose Solutions to a Quality of Care Problem. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 901-907.	2.2	49
276	How to Begin a Quality Improvement Project. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 893-900.	2.2	104
277	How to Sustain Change and Support Continuous Quality Improvement. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 916-924.	2.2	110
278	How to Measure and Interpret Quality Improvement Data. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 908-914.	2.2	33
279	ISCHEMIA in chronic kidney disease: improving the representation of patients with chronic kidney disease in cardiovascular trials. <i>Kidney International</i> , 2016, 89, 1178-1179.	2.6	4
280	Early to Dialyze. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2171.	3.8	12
281	Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2673.	3.8	991
282	Association of Performance-Based and Self-Reported Function-Based Definitions of Frailty with Mortality among Patients Receiving Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 626-632.	2.2	80
283	The effect of frequent hemodialysis on self-reported sleep quality: Frequent Hemodialysis Network Trials. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 984-991.	0.4	16
284	The win ratio approach to analyzing composite outcomes: An application to the EVOLVE trial. <i>Contemporary Clinical Trials</i> , 2016, 48, 119-124.	0.8	21
285	Clinical trials of intensive versus less intensive control of hypertension: HOPE or HYPE?. <i>Kidney International</i> , 2016, 90, 460-462.	2.6	5
286	Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology Collaboration Definitions. <i>American Journal of Nephrology</i> , 2016, 44, 130-140.	1.4	13
287	Metabolic Profiling of Impaired Cognitive Function in Patients Receiving Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 3780-3787.	3.0	47
288	SO0300 ONE YEAR EFFICACY AND SAFETY OF INTRAVENOUS (IV) ETELCALCETIDE (AMG 416) IN PATIENTS ON HEMODIALYSIS (HD) WITH SECONDARY HYPERPARATHYROIDISM (SHPT). <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i13-i14.	0.4	3

#	ARTICLE	IF	CITATIONS
289	Overall Survival in Patients with Localized Prostate Cancer in the US Veterans Health Administration: Is PIVOT Generalizable?. <i>European Urology</i> , 2016, 70, 227-230.	0.9	24
290	Analyzing Health-Related Quality of Life in the EVOLVE Trial. <i>Medical Decision Making</i> , 2016, 36, 965-972.	1.2	19
291	Risk prediction to inform surveillance of chronic kidney disease in the US Healthcare Safety Net: a cohort study. <i>BMC Nephrology</i> , 2016, 17, 57.	0.8	7
292	Rates and Outcomes of Parathyroidectomy for Secondary Hyperparathyroidism in the United States. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1260-1267.	2.2	80
293	Cinacalcet, dialysate calcium concentration, and cardiovascular events in the <scp>EVOLVE</scp> trial. <i>Hemodialysis International</i> , 2016, 20, 421-431.	0.4	19
294	Characterizing Frailty Status in the Systolic Blood Pressure Intervention Trial. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 71, 649-655.	1.7	131
295	How to Use Quality Improvement Tools in Clinical Practice: A Primer for Nephrologists. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 891-892.	2.2	6
296	Patterns and Correlates of Baseline Thiazide-Type Diuretic Prescription in the Systolic Blood Pressure Intervention Trial. <i>Hypertension</i> , 2016, 67, 550-555.	1.3	17
297	The Effect of Increased Frequency of Hemodialysis on Volume-Related Outcomes: A Secondary Analysis of the Frequent Hemodialysis Network Trials. <i>Blood Purification</i> , 2016, 41, 277-286.	0.9	37
298	Misclassification of Obesity by Body Mass Index Among Patients Receiving Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2016, 67, 709-711.	2.1	9
299	Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 3129-3138.	3.0	50
300	Validating Appetite Assessment Tools Among Patients Receiving Hemodialysis. , 2016, 26, 103-110.		25
301	Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 539-546.	2.2	20
302	Managing Hypertension in Patients with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 40-43.	3.0	21
303	Long-Term Effects of Frequent In-Center Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1830-1836.	3.0	91
304	The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial. <i>Journal of Human Hypertension</i> , 2016, 30, 204-209.	1.0	13
305	Sex differences in obesity, dietary habits, and physical activity among urban middle-class Bangladeshis. <i>International Journal of Health Sciences</i> , 2016, 10, 363-72.	0.4	9
306	Effects of physician payment reform on provision of home dialysis. <i>American Journal of Managed Care</i> , 2016, 22, e215-23.	0.8	17

#	ARTICLE	IF	CITATIONS
307	Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial. <i>Value in Health</i> , 2015, 18, 1079-1087.	0.1	16
308	Association of Self-Reported Frailty with Falls and Fractures among Patients New to Dialysis. <i>American Journal of Nephrology</i> , 2015, 42, 134-140.	1.4	84
309	Improving Care after Acute Kidney Injury: A Prospective Time Series Study. <i>Nephron</i> , 2015, 131, 43-50.	0.9	35
310	Red blood cell transfusion, hyperkalemia, and heart failure in advanced chronic kidney disease. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 654-662.	0.9	5
311	Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial. <i>Pharmaceutical Statistics</i> , 2015, 14, 242-251.	0.7	17
312	Time-Updated Systolic Blood Pressure and the Progression of Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2015, 162, 258-265.	2.0	128
313	Longer-term Outcomes of Darbepoetin Alfa Versus Epoetin Alfa in Patients With ESRD Initiating Hemodialysis: A Quasi-experimental Cohort Study. <i>American Journal of Kidney Diseases</i> , 2015, 66, 106-113.	2.1	19
314	A 12-Week, Double-Blind, Placebo-Controlled Trial of Ferric Citrate for the Treatment of Iron Deficiency Anemia and Reduction of Serum Phosphate in Patients With CKD Stages 3-5. <i>American Journal of Kidney Diseases</i> , 2015, 65, 728-736.	2.1	117
315	The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 791-799.	2.2	75
316	Dialysis Plus Do Not Resuscitate—Not a Contradiction. <i>JAMA Internal Medicine</i> , 2015, 175, 1035.	2.6	1
317	Risk Factors for Infection-Related Hospitalization in In-Center Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 2170-2180.	2.2	39
318	Design of a Phase 2 Clinical Trial of an ASK1 Inhibitor, GS-4997, in Patients with Diabetic Kidney Disease. <i>Nephron</i> , 2015, 129, 29-33.	0.9	51
319	Navigating Toward Research Success in Times of Uncertainty: Funding Opportunities for Early Career Investigators in Nephrology. <i>American Journal of Kidney Diseases</i> , 2015, 65, 381-383.	2.1	6
320	Prevalence of chronic kidney disease in two major Indian cities and projections for associated cardiovascular disease. <i>Kidney International</i> , 2015, 88, 178-185.	2.6	53
321	Provider Visits and Early Vascular Access Placement in Maintenance Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1990-1997.	3.0	17
322	Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis. <i>Circulation</i> , 2015, 132, 27-39.	1.6	259
323	Associations of Trimethylamine N-Oxide With Nutritional and Inflammatory Biomarkers and Cardiovascular Outcomes in Patients New to Dialysis. , 2015, 25, 351-356.		141
324	Long-term Effects of Frequent Nocturnal Hemodialysis on Mortality: The Frequent Hemodialysis Network (FHN) Nocturnal Trial. <i>American Journal of Kidney Diseases</i> , 2015, 66, 459-468.	2.1	93

#	ARTICLE	IF	CITATIONS
325	Outcomes of Infection-Related Hospitalization in Medicare Beneficiaries Receiving In-Center Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2015, 65, 754-762.	2.1	40
326	Provider Visit Frequency and Vascular Access Interventions in Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 269-277.	2.2	12
327	Association of bioimpedance spectroscopy-based volume estimation with postdialysis hypotension in patients receiving hemodialysis. <i>Hemodialysis International</i> , 2015, 19, 536-542.	0.4	12
328	Rehospitalizations and Emergency Department Visits after Hospital Discharge in Patients Receiving Maintenance Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 3141-3150.	3.0	69
329	Ambulatory Care after Acute Kidney Injury: An Opportunity to Improve Patient Outcomes. <i>Canadian Journal of Kidney Health and Disease</i> , 2015, 2, 71.	0.6	67
330	Risk prediction models for contrast induced nephropathy: systematic review. <i>BMJ, The</i> , 2015, 351, h4395.	3.0	137
331	Cardiovascular and Renal Outcomes Trials—Is There a Difference?. <i>American Journal of Cardiology</i> , 2015, 116, 982-988.	0.7	3
332	The Effect of Cinacalcet on Calcific Uremic Arteriolopathy Events in Patients Receiving Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 800-807.	2.2	107
333	Evaluating Risk of ESRD in the Urban Poor. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1434-1442.	3.0	13
334	Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1466-1475.	3.0	163
335	Planning for Hemodialysis. , 2015, , 751-764.		0
336	Physician Visits and 30-Day Hospital Readmissions in Patients Receiving Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2079-2087.	3.0	82
337	Bardoxolone Methyl in Type 2 Diabetes and Advanced Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2014, 370, 1767-1769.	13.9	27
338	Prognostic Stratification in Older Adults Commencing Dialysis. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2014, 69, 1033-1039.	1.7	20
339	Comparison of Hospitalization Rates among For-Profit and Nonprofit Dialysis Facilities. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 73-81.	2.2	31
340	Effects of daily hemodialysis on heart rate variability: results from the Frequent Hemodialysis Network (FHN) Daily Trial. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 168-178.	0.4	45
341	Characteristics and Performance of Minority-Serving Dialysis Facilities. <i>Health Services Research</i> , 2014, 49, 971-991.	1.0	20
342	Anticoagulation, delivered dose and outcomes in <sc>CRRT</sc>: The program to improve care in acute renal disease (<sc>PICARD</sc>). <i>Hemodialysis International</i> , 2014, 18, 641-649.	0.4	16

#	ARTICLE	IF	CITATIONS
343	Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. <i>International Journal of Cancer</i> , 2014, 134, 2245-2252.	2.3	114
344	Effects of Frequent Hemodialysis on Perceived Caregiver Burden in the Frequent Hemodialysis Network Trials. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 936-942.	2.2	50
345	Association between Body Composition and Frailty among Prevalent Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 381-389.	3.0	134
346	Medicare Reimbursement Reform for Provider Visits and Health Outcomes in Patients on Hemodialysis. <i>Forum for Health Economics and Policy</i> , 2014, 17, 53-77.	0.2	12
347	Thienopyridine Use After Coronary Stenting in Low Income Patients Enrolled in Medicare Part D Receiving Maintenance Dialysis. <i>Journal of the American Heart Association</i> , 2014, 3, e001356.	1.6	10
348	Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The Evaluation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) Trial. <i>Journal of the American Heart Association</i> , 2014, 3, e001363.	1.6	105
349	Estimation of 24-Hour Urine Phosphate Excretion From Spot Urine Collection: Development of a Predictive Equation. , 2014, 24, 194-199.		15
350	Reply. <i>Urology</i> , 2014, 83, 779-780.	0.5	0
351	Lowering Blood Pressure to Lower the Risk of Cardiovascular Events in CKD. <i>American Journal of Kidney Diseases</i> , 2014, 63, 900-902.	2.1	1
352	Utilization of Renal Mass Biopsy in Patients With Renal Cell Carcinoma. <i>Urology</i> , 2014, 83, 774-780.	0.5	85
353	A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1053-1060.	0.4	64
354	Visit-to-visit systolic blood pressure variability and outcomes in hemodialysis. <i>Journal of Human Hypertension</i> , 2014, 28, 18-24.	1.0	59
355	Temporal Trends in the Incidence, Treatment and Outcomes of Hip Fracture After First Kidney Transplantation in the United States. <i>American Journal of Transplantation</i> , 2014, 14, 943-951.	2.6	70
356	Risk Factors for Heart Failure in Patients With Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated With Bardoxolone Methyl. <i>Journal of Cardiac Failure</i> , 2014, 20, 953-958.	0.7	139
357	Urine Electrolyte Composition and Diuretic Therapy in Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 697-698.	1.6	4
358	Long-Term Safety and Efficacy of a Novel Iron-Containing Phosphate Binder, JTT-751, in Patients Receiving Hemodialysis. , 2014, 24, 261-267.		51
359	Calibration of the Brief Food Frequency Questionnaire Among Patients on Dialysis. , 2014, 24, 151-156.e1.		11
360	Comparison of Self-reportâ™Based and Physical Performanceâ™Based Frailty Definitions Among Patients Receiving Maintenance Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2014, 64, 600-607.	2.1	75

#	ARTICLE	IF	CITATIONS
361	Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. <i>Annals of Internal Medicine</i> , 2014, 160, 143.	2.0	0
362	Reforming Medicare's Dialysis Payment Policies: Implications for Patients with Secondary Hyperparathyroidism. <i>Health Services Research</i> , 2014, 49, n/a-n/a.	1.0	0
363	Changes in serum inflammatory markers are associated with changes in apolipoprotein A1 but not B after the initiation of dialysis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 430-437.	0.4	10
364	Characteristics and Performance of Minority-Serving Dialysis Facilities. , 2014, 49, 971.		2
365	Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON). <i>American Journal of Nephrology</i> , 2013, 37, 212-222.	1.4	82
366	Trends in Acute Kidney Injury, Associated Use of Dialysis, and Mortality After Cardiac Surgery, 1999 to 2008. <i>Annals of Thoracic Surgery</i> , 2013, 95, 20-28.	0.7	82
367	Cost-Effectiveness of Statins for Primary Cardiovascular Prevention in Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1250-1258.	1.2	47
368	Effects of 6-Times-Weekly Versus 3-Times-Weekly Hemodialysis on Depressive Symptoms and Self-reported Mental Health: Frequent Hemodialysis Network (FHN) Trials. <i>American Journal of Kidney Diseases</i> , 2013, 61, 748-758.	2.1	52
369	Longitudinal Measures of Serum Albumin and Prealbumin Concentrations in Incident Dialysis Patients: The Comprehensive Dialysis Study. , 2013, 23, 91-97.		32
370	66 DIABETIC SEVERITY AND RISK OF KIDNEY STONE DISEASE. <i>Journal of Urology</i> , 2013, 189, .	0.2	0
371	Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2013, 369, 2492-2503.	13.9	844
372	The Clinical Course of Treated Hyperparathyroidism Among Patients Receiving Hemodialysis and the Effect of Cinacalcet: The EVOLVE Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 4834-4844.	1.8	63
373	Sensitization from transfusion in patients awaiting primary kidney transplant. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2908-2918.	0.4	69
374	Cinacalcet for Cardiovascular Disease in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2013, 368, 1842-1845.	13.9	16
375	Association of Physical Activity with Survival among Ambulatory Patients on Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 248-253.	2.2	117
376	Piecewise Analysis of Patient Survival after Onset of AKI. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1679-1684.	2.2	15
377	Temporal Trends in the Incidence, Treatment, and Outcomes of Hip Fracture in Older Patients Initiating Dialysis in the United States. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1336-1342.	2.2	67
378	Effects of Frequent Hemodialysis on Ventricular Volumes and Left Ventricular Remodeling. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 2106-2116.	2.2	70

#	ARTICLE	IF	CITATIONS
379	Variation in Nephrologist Visits to Patients on Hemodialysis across Dialysis Facilities and Geographic Locations. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 987-994.	2.2	33
380	Oh! What a Tangled Web We Weave. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1066-1067.	2.2	2
381	Systematic evaluation of environmental and behavioural factors associated with all-cause mortality in the United States National Health and Nutrition Examination Survey. <i>International Journal of Epidemiology</i> , 2013, 42, 1795-1810.	0.9	109
382	Prevention of Contrast-Induced AKI. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1618-1631.	2.2	94
383	Effect of frequent hemodialysis on residual kidney function. <i>Kidney International</i> , 2013, 83, 949-958.	2.6	186
384	Baseline characteristics in the Bardoxolone methyl Evaluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2841-2850.	0.4	21
385	High prevalence of type 2 diabetes among the urban middle class in Bangladesh. <i>BMC Public Health</i> , 2013, 13, 1032.	1.2	39
386	Cost-Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. <i>Annals of Internal Medicine</i> , 2013, 159, 382.	2.0	56
387	Venous Thromboembolism. <i>Circulation</i> , 2012, 126, 1937-1938.	1.6	1
388	Determinants of Left Ventricular Mass in Patients on Hemodialysis. <i>Circulation: Cardiovascular Imaging</i> , 2012, 5, 251-261.	1.3	87
389	Ongoing Clinical Trials in AKI. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 861-873.	2.2	76
390	Effects of Six versus Three Times per Week Hemodialysis on Physical Performance, Health, and Functioning. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 782-794.	2.2	95
391	Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2872-2879.	0.4	45
392	The effect of frequent hemodialysis on nutrition and body composition: Frequent Hemodialysis Network Trial. <i>Kidney International</i> , 2012, 82, 90-99.	2.6	65
393	Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2012, 367, 2482-2494.	13.9	805
394	Frailty, Dialysis Initiation, and Mortality in End-Stage Renal Disease. <i>Archives of Internal Medicine</i> , 2012, 172, 1071-7.	4.3	267
395	Homelessness and CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 1094-1102.	2.2	28
396	Validation of Reported Predialysis Nephrology Care of Older Patients Initiating Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1078-1085.	3.0	39

#	ARTICLE	IF	CITATIONS
397	Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney. Journal of the American Society of Nephrology: JASN, 2012, 23, 1663-1673.	3.0	88
398	Toward the Optimal dose Metric in Continuous Renal Replacement Therapy. International Journal of Artificial Organs, 2012, 35, 413-424.	0.7	22
399	Effects of Phosphate Binders in Moderate CKD. Journal of the American Society of Nephrology: JASN, 2012, 23, 1407-1415.	3.0	486
400	Acute Kidney Injury and Mortality in Hospitalized Patients. American Journal of Nephrology, 2012, 35, 349-355.	1.4	399
401	Effects of Frequent Hemodialysis on Measures of CKD Mineral and Bone Disorder. Journal of the American Society of Nephrology: JASN, 2012, 23, 727-738.	3.0	137
402	Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols. Hemodialysis International, 2012, 16, 188-197.	0.4	22
403	Challenges to enrollment and randomization of the frequent hemodialysis network (FHN) daily trial. Journal of Nephrology, 2012, 25, 302-309.	0.9	22
404	The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial. Kidney International, 2011, 80, 1080-1091.	2.6	450
405	Association of Self-reported Physical Activity With Laboratory Markers of Nutrition and Inflammation: The Comprehensive Dialysis Study. , 2011, 21, 429-437.		39
406	Chronic Kidney Disease and Cardiovascular Therapeutics. Journal of the American College of Cardiology, 2011, 58, 1162-1164.	1.2	5
407	Assessment and management of vascular disease risk in patients with chronic kidney disease. Journal of Clinical Lipidology, 2011, 5, 251-260.	0.6	0
408	The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrology Dialysis Transplantation, 2011, 26, 1327-1339.	0.4	491
409	The Phosphate Binder Equivalent Dose. Seminars in Dialysis, 2011, 24, 41-49.	0.7	114
410	Baseline Physical Performance, Health, and Functioning of Participants in the Frequent Hemodialysis Network (FHN) Trial. American Journal of Kidney Diseases, 2011, 57, 101-112.	2.1	63
411	Baseline Characteristics of Participants in the Frequent Hemodialysis Network (FHN) Daily and Nocturnal Trials. American Journal of Kidney Diseases, 2011, 57, 90-100.	2.1	36
412	The 2011 ESRD Prospective Payment System: An Uncontrolled Experiment. American Journal of Kidney Diseases, 2011, 57, 542-546.	2.1	15
413	Sepsis as a cause and consequence of acute kidney injury: Program to Improve Care in Acute Renal Disease. Intensive Care Medicine, 2011, 37, 241-248.	3.9	239
414	Modeled Urea Distribution Volume and Mortality in the HEMO Study. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1129-1138.	2.2	15

#	ARTICLE	IF	CITATIONS
415	Racial Ethnic Differences in Rates and Determinants of Deceased Donor Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 743-751.	3.0	103
416	Model to Predict Mortality in Critically Ill Adults with Acute Kidney Injury. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2114-2120.	2.2	88
417	Predialysis Nephrology Care of Older Patients Approaching End-stage Renal Disease. <i>Archives of Internal Medicine</i> , 2011, 171, 1371.	4.3	62
418	Risk of Cardiovascular Events after Infection-Related Hospitalizations in Older Patients on Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1708-1713.	2.2	45
419	Effluent Volume in Continuous Renal Replacement Therapy Overestimates the Delivered Dose of Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 467-475.	2.2	100
420	Burden on caregivers as perceived by hemodialysis patients in the Frequent Hemodialysis Network (FHN) trials. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2316-2322.	0.4	85
421	World Kidney Day 2011. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 397-398.	3.0	5
422	Aspirin and Arteriovenous Graft Thrombosis in Hemodialysis: Just What the Doctor Ordered?. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 595-597.	3.0	3
423	Systolic blood pressure and mortality in prevalent haemodialysis patients in the HEMO study. <i>Journal of Human Hypertension</i> , 2011, 25, 98-105.	1.0	45
424	Projected Effect of Dietary Salt Reductions on Future Cardiovascular Disease. <i>Obstetrical and Gynecological Survey</i> , 2010, 65, 441-442.	0.2	4
425	Infection-Related Hospitalizations in Older Patients With ESRD. <i>American Journal of Kidney Diseases</i> , 2010, 56, 522-530.	2.1	95
426	Off-Label Use of Phosphate Binders in Non-Dialysis-Dependent CKD. <i>American Journal of Kidney Diseases</i> , 2010, 56, 813-816.	2.1	1
427	On the relative safety of intravenous iron formulations: New answers, new questions. <i>American Journal of Hematology</i> , 2010, 85, 643-644.	2.0	14
428	<i>Insight</i>: Effects of Reduced Intradialytic Urea Generation Rate and Residual Renal Clearance on Modeled Urea Distribution Volume and <i>Kt/V</i> in Conventional, Daily, and Nocturnal Dialysis. <i>Seminars in Dialysis</i> , 2010, 23, 19-24.	0.7	7
429	Reexploring Differences among For-Profit and Nonprofit Dialysis Providers. <i>Health Services Research</i> , 2010, 45, 633-646.	1.0	44
430	GFR estimating equations, CKD prevalence and the public health. <i>Journal of Internal Medicine</i> , 2010, 267, 354-356.	2.7	1
431	Determinants of Cardiac Autonomic Dysfunction in ESRD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1821-1827.	2.2	61
432	Can Rescaling Dose of Dialysis to Body Surface Area in the HEMO Study Explain the Different Responses to Dose in Women versus Men?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1628-1636.	2.2	63

#	ARTICLE	IF	CITATIONS
433	Low level of self-reported physical activity in ambulatory patients new to dialysis. <i>Kidney International</i> , 2010, 78, 1164-1170.	2.6	146
434	Hyperparathyroidism with hypercalcaemia in chronic kidney disease: primary or tertiary?. <i>CKJ: Clinical Kidney Journal</i> , 2010, 3, 366-371.	1.4	6
435	Weekend Hospital Admission, Acute Kidney Injury, and Mortality. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 845-851.	3.0	97
436	Kidney Disease, Hospitalized Hypertension, and Cardiovascular Events: Cause or Consequence?. <i>Circulation</i> , 2010, 121, 2160-2161.	1.6	3
437	Comparison of methods for estimating glomerular filtration rate in critically ill patients with acute kidney injury. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 102-107.	0.4	97
438	Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1916-1923.	0.4	38
439	Chronic Kidney Disease in the Urban Poor. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 828-835.	2.2	63
440	In-Center Hemodialysis Six Times per Week versus Three Times per Week. <i>New England Journal of Medicine</i> , 2010, 363, 2287-2300.	13.9	898
441	Standard Kt/Vurea: a method of calculation that includes effects of fluid removal and residual kidney clearance. <i>Kidney International</i> , 2010, 77, 637-644.	2.6	81
442	Shorter dialysis times are associated with higher mortality among incident hemodialysis patients. <i>Kidney International</i> , 2010, 77, 630-636.	2.6	68
443	Fluid accumulation, recognition and staging of acute kidney injury in critically-ill patients. <i>Critical Care</i> , 2010, 14, R82.	2.5	342
444	Projected Effect of Dietary Salt Reductions on Future Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2010, 362, 590-599.	13.9	1,023
445	Regional Variation in Kidney Transplant Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 152-159.	2.2	11
446	Phosphorus binders and survival: need for randomized trials. <i>Nature Reviews Nephrology</i> , 2009, 5, 368-370.	4.1	1
447	Functional Status of Elderly Adults before and after Initiation of Dialysis. <i>New England Journal of Medicine</i> , 2009, 361, 1539-1547.	13.9	849
448	Fetuin-A and Change in Body Composition in Older Persons. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 4492-4498.	1.8	44
449	Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. <i>Kidney International</i> , 2009, 76, 893-899.	2.6	483
450	The Comprehensive Dialysis Study (CDS). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 645-650.	2.2	48

#	ARTICLE	IF	CITATIONS
451	Preexisting Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1914-1919.	2.2	91
452	Is there "Cherry Picking" in the ESRD Program? Perceptions from a Dialysis Provider Survey. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 772-777.	2.2	27
453	Characteristics of Uninsured Americans with Chronic Kidney Disease. <i>Journal of General Internal Medicine</i> , 2009, 24, 917-922.	1.3	45
454	The relationship between laboratory-based outcome measures and mortality in end-stage renal disease: A systematic review. <i>Hemodialysis International</i> , 2009, 13, 347-359.	0.4	40
455	A randomized double-blind pilot study of serum phosphorus normalization in chronic kidney disease: A new paradigm for clinical outcomes studies in nephrology. <i>Hemodialysis International</i> , 2009, 13, 360-362.	0.4	20
456	Increased fluid intake does not augment capacity to lay down new collagen in nursing home residents at risk for pressure ulcers: A randomized, controlled clinical trial. <i>Wound Repair and Regeneration</i> , 2009, 17, 780-788.	1.5	12
457	An Empiric Estimate of the Value of Life: Updating the Renal Dialysis Cost-Effectiveness Standard. <i>Value in Health</i> , 2009, 12, 80-87.	0.1	166
458	Intensity of renal replacement therapy in acute kidney injury: perspective from within the Acute Renal Failure Trial Network Study. <i>Critical Care</i> , 2009, 13, 310.	2.5	53
459	Frailty and Chronic Kidney Disease: The Third National Health and Nutrition Evaluation Survey. <i>American Journal of Medicine</i> , 2009, 122, 664-671.e2.	0.6	279
460	Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. <i>Kidney International</i> , 2009, 76, 422-427.	2.6	888
461	Medication errors in chronic kidney disease: one piece in the patient safety puzzle. <i>Kidney International</i> , 2009, 76, 1123-1125.	2.6	28
462	<i>Dialysis Research</i>: Surface Area Normalized <i>Kt</i>/<i>V</i>: A Method of Rescaling Dialysis Dose to Body Surface Area—Implications for Different Size Patients by Gender. <i>Seminars in Dialysis</i> , 2008, 21, 415-421.	0.7	58
463	<i>Editorials</i>: Comparison of Proposed Alternative Methods for Rescaling Dialysis Dose: Resting Energy Expenditure, High Metabolic Rate Organ Mass, Liver Size, and Body Surface Area. <i>Seminars in Dialysis</i> , 2008, 21, 377-384.	0.7	45
464	Neighborhood Poverty and Kidney Transplantation Among US Asians and Pacific Islanders with End-stage Renal Disease. <i>American Journal of Transplantation</i> , 2008, 8, 2402-2409.	2.6	43
465	The risk of acute renal failure in patients with chronic kidney disease. <i>Kidney International</i> , 2008, 74, 101-107.	2.6	448
466	Trends and Outcomes Associated With Serum Albumin Concentration Among Incident Dialysis Patients in the United States. , 2008, 18, 323-331.		31
467	Kidney dysfunction and fatal cardiovascular disease—an association independent of atherosclerotic events: Results from the Health, Aging, and Body Composition (Health ABC) study. <i>American Heart Journal</i> , 2008, 155, 62-68.	1.2	89
468	Optimal Initiation and Management of Dialysis Therapy. <i>Operations Research</i> , 2008, 56, 1428-1449.	1.2	36

#	ARTICLE	IF	CITATIONS
469	Higher Serum Creatinine Concentrations in Black Patients with Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 992-997.	2.2	62
470	A Comparison of Change in Measured and Estimated Glomerular Filtration Rate in Patients with Nondiabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1332-1338.	2.2	61
471	Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2311-2318.	0.4	92
472	Diagnosis, Epidemiology and Outcomes of Acute Kidney Injury. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 844-861.	2.2	431
473	Intensity of Renal Support in Critically Ill Patients with Acute Kidney Injury. <i>New England Journal of Medicine</i> , 2008, 359, 7-20.	13.9	1,611
474	Lessons for Successful Study Enrollment from the Veterans Affairs/National Institutes of Health Acute Renal Failure Trial Network Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 955-961.	2.2	27
475	Cost-Effectiveness of Frequent In-Center Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 1792-1797.	3.0	40
476	Toward the Promise of Renal Replacement Therapy. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 839-840.	3.0	10
477	Phosphorus balance and mineral metabolism with 3h daily hemodialysis. <i>Kidney International</i> , 2007, 71, 336-342.	2.6	72
478	Frequent Hemodialysis Network (FHN) randomized trials: Study design. <i>Kidney International</i> , 2007, 71, 349-359.	2.6	176
479	Association of Fetuin-A With Mitral Annular Calcification and Aortic Stenosis Among Persons With Coronary Heart Disease. <i>Circulation</i> , 2007, 115, 2533-2539.	1.6	147
480	Significance of Frailty among Dialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 2960-2967.	3.0	545
481	Race and Mortality after Acute Renal Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 2740-2748.	3.0	41
482	Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 898-905.	2.2	144
483	Octogenarians and Nonagenarians Starting Dialysis in the United States. <i>Annals of Internal Medicine</i> , 2007, 146, 177.	2.0	446
484	Predictive and pathogenetic value of plasma biomarkers for acute kidney injury in patients with acute lung injury*. <i>Critical Care Medicine</i> , 2007, 35, 2755-2761.	0.4	131
485	Community-based incidence of acute renal failure. <i>Kidney International</i> , 2007, 72, 208-212.	2.6	461
486	Chronic Kidney Disease Mineral Bone Disorder and Health-Related Quality of Life Among Incident End-Stage Renal-Disease Patients. , 2007, 17, 305-313.		20

#	ARTICLE	IF	CITATIONS
487	Association of Cystatin C With Mortality, Cardiovascular Events, and Incident Heart Failure Among Persons With Coronary Heart Disease. <i>Circulation</i> , 2007, 115, 173-179.	1.6	300
488	Kidney Function as a Predictor of Loss of Lean Mass in Older Adults: Health, Aging and Body Composition Study. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 1578-1584.	1.3	30
489	A Simulation Model to Estimate the Cost and Effectiveness of Alternative Dialysis Initiation Strategies. <i>Medical Decision Making</i> , 2006, 26, 535-549.	1.2	19
490	Acute renal failure after endovascular vs open repair of abdominal aortic aneurysm. <i>Journal of Vascular Surgery</i> , 2006, 43, 460-466.e2.	0.6	151
491	Cystatin C, Left Ventricular Hypertrophy, and Diastolic Dysfunction: Data From the Heart and Soul Study. <i>Journal of Cardiac Failure</i> , 2006, 12, 601-607.	0.7	68
492	Association of body size with health status in patients beginning dialysis. <i>American Journal of Clinical Nutrition</i> , 2006, 83, 543-549.	2.2	46
493	Chronic Kidney Disease and Functional Limitation in Older People: Health, Aging and Body Composition Study. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 750-756.	1.3	177
494	The tortoise and hare on hemodialysis: Does slow and steady win the race?. <i>Kidney International</i> , 2006, 70, 24-25.	2.6	8
495	Mortality after acute renal failure: Models for prognostic stratification and risk adjustment. <i>Kidney International</i> , 2006, 70, 1120-1126.	2.6	245
496	Challenging the Validity of the EPO Index. <i>American Journal of Kidney Diseases</i> , 2006, 47, 166.e1-166.e13.	2.1	50
497	PTH and the Risks for Hip, Vertebral, and Pelvic Fractures Among Patients on Dialysis. <i>American Journal of Kidney Diseases</i> , 2006, 47, 149-156.	2.1	271
498	Less-than-subtotal parathyroidectomy increases the risk of persistent/recurrent hyperparathyroidism after parathyroidectomy in tertiary hyperparathyroidism after renal transplantation. <i>Surgery</i> , 2006, 140, 990-999.	1.0	56
499	Fetuin-A and kidney function in persons with coronary artery disease—data from the heart and soul study. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2144-2151.	0.4	67
500	Correlates and outcomes of dementia among dialysis patients: the Dialysis Outcomes and Practice Patterns Study. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2543-2548.	0.4	198
501	Cystatin C and Measures of Physical Function in Elderly Adults: The Health, Aging, and Body Composition (HABC) Study. <i>American Journal of Epidemiology</i> , 2006, 164, 1180-1189.	1.6	99
502	Survival by Dialysis Modality in Critically Ill Patients with Acute Kidney Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 3132-3138.	3.0	95
503	Timing of Initiation of Dialysis in Critically Ill Patients with Acute Kidney Injury. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 915-919.	2.2	299
504	The Case against Calcium-Based Phosphate Binders. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 697-703.	2.2	89

#	ARTICLE	IF	CITATIONS
505	Cystatin C and Mortality Risk in the Elderly: The Health, Aging, and Body Composition Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 254-261.	3.0	195
506	Evolving Practices in Critical Care and Potential Implications for Management of Acute Kidney Injury. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 869-873.	2.2	23
507	Studying the Prevention of Acute Kidney Injury: Lessons from an 18th-Century Mathematician: Table 1.. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 1124-1127.	2.2	27
508	Cinacalcet Hydrochloride (Sensipar) in Hemodialysis Patients on Active Vitamin D Derivatives with Controlled PTH and Elevated Calcium Å — Phosphate. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 305-312.	2.2	64
509	Update on adverse drug events associated with parenteral iron. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 378-382.	0.4	405
510	Tesio Catheter Access for Long-term Maintenance Hemodialysis. <i>Radiology</i> , 2006, 241, 284-290.	3.6	15
511	Risks for End-Stage Renal Disease, Cardiovascular Events, and Death in Hispanic versus Non-Hispanic White Adults with Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 2892-2899.	3.0	140
512	Declining Mortality in Patients with Acute Renal Failure, 1988 to 2002. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1143-1150.	3.0	499
513	Validity of International Classification of Diseases, Ninth Revision, Clinical Modification Codes for Acute Renal Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1688-1694.	3.0	415
514	Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. <i>Kidney International</i> , 2005, 68, 1793-1800.	2.6	499
515	Prealbumin, mortality, and cause-specific hospitalization in hemodialysis patients. <i>Kidney International</i> , 2005, 68, 2794-2800.	2.6	66
516	Health-related quality of life and estimates of utility in chronic kidney disease. <i>Kidney International</i> , 2005, 68, 2801-2808.	2.6	235
517	Achieving NKF-K/DOQI $\text{â„$ bone metabolism and disease treatment goals with cinacalcet HCl. <i>Kidney International</i> , 2005, 67, 760-771.	2.6	290
518	Chronic kidney disease and cognitive impairment in menopausal women. <i>American Journal of Kidney Diseases</i> , 2005, 45, 66-76.	2.1	152
519	Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: A randomized clinical trial. <i>Arthritis and Rheumatism</i> , 2005, 52, 290-295.	6.7	104
520	Insulin resistance in critically ill patients with acute renal failure. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 289, F259-F264.	1.3	108
521	Medicare ESRD Prospective Payment System: Weighing the Evidence. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1164-1165.	3.0	13
522	Differential Mortality and Transplantation Rates among Asians and Pacific Islanders with ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 3711-3720.	3.0	45

#	ARTICLE	IF	CITATIONS
523	Beyond Framingham: Cardiovascular Risk Profiling in ESRD. Journal of the American Society of Nephrology: JASN, 2005, 16, 1539-1541.	3.0	26
524	Suicide in the United States End-Stage Renal Disease Program. Journal of the American Society of Nephrology: JASN, 2005, 16, 774-781.	3.0	144
525	Calcification or Classification?. Journal of the American Society of Nephrology: JASN, 2005, 16, 293-295.	3.0	14
526	Control of Hypertension in Adults With Chronic Kidney Disease in the United States. Hypertension, 2005, 45, 1119-1124.	1.3	151
527	Metabolic Syndrome and the Risk for Chronic Kidney Disease among Nondiabetic Adults. Journal of the American Society of Nephrology: JASN, 2005, 16, 2134-2140.	3.0	614
528	Angiotensin Receptor Blockade and Arterial Compliance in Chronic Kidney Disease: A Pilot Study. American Journal of Nephrology, 2005, 25, 393-399.	1.4	17
529	Self-reported appetite, hospitalization and death in haemodialysis patients: findings from the Hemodialysis (HEMO) Study. Nephrology Dialysis Transplantation, 2005, 20, 2765-2774.	0.4	115
530	Acute Kidney Injury, Mortality, Length of Stay, and Costs in Hospitalized Patients. Journal of the American Society of Nephrology: JASN, 2005, 16, 3365-3370.	3.0	2,887
531	Dialysis session length (∆) as a determinant of the adequacy of dialysis. Seminars in Nephrology, 2005, 25, 90-95.	0.6	17
532	Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. American Heart Journal, 2005, 149, 820-825.	1.2	225
533	Serum Blood Urea Nitrogen as an Independent Marker of Subsequent Mortality Among Patients With Acute Coronary Syndromes and Normal to Mildly Reduced Glomerular Filtration Rates. Journal of the American College of Cardiology, 2005, 45, 1781-1786.	1.2	117
534	Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis. Journal of the American Society of Nephrology: JASN, 2004, 15, 2208-2218.	3.0	2,350
535	"Renalism": Inappropriately Low Rates of Coronary Angiography in Elderly Individuals with Renal Insufficiency. Journal of the American Society of Nephrology: JASN, 2004, 15, 2462-2468.	3.0	281
536	Chronic Kidney Disease, Cardiovascular Risk, and Response to Angiotensin-Converting Enzyme Inhibition After Myocardial Infarction. Circulation, 2004, 110, 3667-3673.	1.6	185
537	A 43-Year-Old Woman With Chronic Renal Insufficiency. JAMA - Journal of the American Medical Association, 2004, 291, 1252.	3.8	3
538	Determinants of progressive vascular calcification in haemodialysis patients. Nephrology Dialysis Transplantation, 2004, 19, 1489-1496.	0.4	258
539	Coronary and aortic calcifications in patients new to dialysis. Hemodialysis International, 2004, 8, 265-272.	0.4	35
540	Vector length as a proxy for the adequacy of ultrafiltration in hemodialysis. Kidney International, 2004, 66, 1266-1271.	2.6	99

#	ARTICLE	IF	CITATIONS
541	Spectrum of acute renal failure in the intensive care unit: The PICARD experience. <i>Kidney International</i> , 2004, 66, 1613-1621.	2.6	763
542	Cognitive Impairment in Chronic Kidney Disease. <i>Journal of the American Geriatrics Society</i> , 2004, 52, 1863-1869.	1.3	380
543	Physical and sexual function in women with chronic kidney disease. <i>American Journal of Kidney Diseases</i> , 2004, 43, 868-876.	2.1	37
544	Screening to prevent coronary events or screening to detect obstruction?. <i>American Journal of Kidney Diseases</i> , 2004, 43, 940.	2.1	3
545	Decrease in Thoracic Vertebral Bone Attenuation With Calcium-Based Phosphate Binders in Hemodialysis. <i>Journal of Bone and Mineral Research</i> , 2004, 20, 764-772.	3.1	132
546	On the relative safety of parenteral iron formulations. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1571-1575.	0.4	136
547	Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization. <i>New England Journal of Medicine</i> , 2004, 351, 1296-1305.	13.9	9,843
548	Association of body size with outcomes among patients beginning dialysis. <i>American Journal of Clinical Nutrition</i> , 2004, 80, 324-332.	2.2	248
549	Analgesia in patients with ESRD: a review of available evidence. <i>American Journal of Kidney Diseases</i> , 2003, 42, 217-228.	2.1	136
550	Reasons for non-enrollment in a cohort study of ARF: the Program to Improve Care in Acute Renal Disease (PICARD) experience and implications for a clinical trials network. <i>American Journal of Kidney Diseases</i> , 2003, 42, 507-512.	2.1	28
551	The Decline in Residual Renal Function in Hemodialysis Is Slow and Age Dependent. <i>Hemodialysis International</i> , 2003, 7, 17-22.	0.4	13
552	Inflammatory markers are unrelated to physical activity, performance, and functioning in hemodialysis. <i>Advances in Chronic Kidney Disease</i> , 2003, 10, 232-240.	2.2	9
553	Acute Renal Failure Definitions and Classification: Time for Change?. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2178-2187.	3.0	463
554	Slowing the Progression of Vascular Calcification in Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, S310-S314.	3.0	45
555	The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, S148-S153.	3.0	545
556	The Effects of Sevelamer and Calcium Acetate on Proxies of Atherosclerotic and Arteriosclerotic Vascular Disease in Hemodialysis Patients. <i>American Journal of Nephrology</i> , 2003, 23, 307-314.	1.4	98
557	In critically ill patients with acute renal failure, outcomes, not dollars, should drive modality choice *. <i>Critical Care Medicine</i> , 2003, 31, 644-646.	0.4	17
558	Diuretics, Mortality, and Nonrecovery of Renal Function in Acute Renal Failure. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 2547.	3.8	604

#	ARTICLE	IF	CITATIONS
559	The Severity of Secondary Hyperparathyroidism in Chronic Renal Insufficiency is GFR-Dependent, Race-Dependent, and Associated with Cardiovascular Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 2762-2769.	3.0	157
560	Refining Predictive Models in Critically Ill Patients with Acute Renal Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1350-1357.	3.0	328
561	Cardiac calcification in adult hemodialysis patients. <i>Journal of the American College of Cardiology</i> , 2002, 39, 695-701.	1.2	1,020
562	Inflammatory markers are unrelated to physical activity, performance, and functioning in hemodialysis. , 2002, 12, 170-176.		19
563	Renal insufficiency with monoclonal gammopathy and urticarial vasculitis. <i>American Journal of Kidney Diseases</i> , 2002, 39, 203-207.	2.1	6
564	Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. <i>Kidney International</i> , 2002, 62, 245-252.	2.6	1,316
565	Suspected iron dextran-related adverse drug events in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2001, 37, 743-749.	2.1	126
566	Gridlock on the Road to Kidney Transplantation. <i>American Journal of Kidney Diseases</i> , 2001, 37, 435-437.	2.1	7
567	Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. <i>Kidney International</i> , 2001, 60, 333-340.	2.6	182
568	Validation of questionnaires to estimate physical activity and functioning in end-stage renal disease. <i>Kidney International</i> , 2001, 59, 1121-1127.	2.6	214
569	“Wishing Don’t Make it So” Why We Need a Randomized Clinical Trial of High-Intensity Hemodialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2850-2853.	3.0	20
570	Hyperparathyroidism and dialysis vintage. <i>Clinical Nephrology</i> , 2000, 54, 295-300.	0.4	27
571	Metabolic and Monetary Costs of Avoidable Parenteral Nutrition Use. <i>Journal of Parenteral and Enteral Nutrition</i> , 1999, 23, 109-113.	1.3	94
572	Issues in Evaluating the Cost-Effectiveness of Dialysis. <i>Seminars in Dialysis</i> , 1999, 12, 355-358.	0.7	3
573	A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. <i>Clinical Nephrology</i> , 1999, 51, 18-26.	0.4	110
574	Dialysis: Cost-effective SUPPORT for patients with acute renal failure. <i>American Journal of Kidney Diseases</i> , 1998, 31, 545-549.	2.1	6
575	Current and Future Therapies for the Medical Management of Secondary Hyperparathyroidism. <i>Seminars in Dialysis</i> , 1998, 11, 267-270.	0.7	5
576	Predictors of mortality and the provision of dialysis in patients with acute tubular necrosis. The Auriculin Anaritide Acute Renal Failure Study Group.. <i>Journal of the American Society of Nephrology: JASN</i> , 1998, 9, 692-698.	3.0	190

#	ARTICLE	IF	CITATIONS
577	Assessing the Nutritional Status of Patients with End-Stage Renal Disease. <i>Seminars in Dialysis</i> , 1997, 10, 108-114.	0.7	12
578	Intensity of Dialysis in Established Acute Renal Failure. <i>Seminars in Dialysis</i> , 1996, 9, 476-480.	0.7	7
579	Performance characteristics of a dialysis-related amyloidosis questionnaire.. <i>Journal of the American Society of Nephrology: JASN</i> , 1996, 7, 1235-1240.	3.0	8
580	Cost-effectiveness of cancer screening in end-stage renal disease. <i>Archives of Internal Medicine</i> , 1996, 156, 1345-50.	4.3	13
581	Nutritional assessment with bioelectrical impedance analysis in maintenance hemodialysis patients.. <i>Journal of the American Society of Nephrology: JASN</i> , 1995, 6, 75-81.	3.0	236
582	Non-immunologic predictors of chronic renal allograft failure: data from the United Network of Organ Sharing. <i>Kidney International, Supplement</i> , 1995, 52, S48-51.	0.1	4
583	Association of Apolipoprotein L-1 polymorphisms with blood pressure in three multi-ethnic African studies. <i>Journal of Global Health Reports</i> , 0, , .	1.0	0